DHX29

Across TCGA pan-cancer cohorts, DHX29 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DHX29 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DHX29 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DHX29 expression acts as an unfavorable survival marker, although some lineages such as HNSC and COAD show a favorable association.

HNSC, LSCC, and GBM are the cancer types where DHX29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.941	0.752	.003	41	view →
LSCC	OS	Tertile	III,IV	0.611	0.986	.008	16	view →
GBM	DFS	Median	All	0.635	0.790	.003	13	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.912	.038	12	view →
LUAD	DFS	Median	All	0.887	1.000	.012	11	view →
CCRCC	OS	Median	III,IV	0.485	1.000	.036	8	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DHX29–HNSC (OS)

Open the HNSC breakdown →